38 results about "Flunarizine Hydrochloride" patented technology

The invention discloses a film agent quickly dissolved in the oral cavity and a preparation method thereof. The film agent consists of the following components in percentage by weight: 0.1 to 70 percent of medicinal active ingredients, 30 to 90 percent of water-soluble film forming material, 2 to 20 percent of plasticizer, 0 to 5 percent of disintegrating agent, and 1 to 20 percent of water, wherein the medicinal active ingredients are selected from modified or non-modified cobra venom, sumatriptan succinate, ergotamine dihydrogen tartrate and lomerizine hydrochloride or flunarizine hydrochloride. The film agent is quick in response, and avoids decomposition in gastrointestinal tracts due to oral administration to reduce the treatment effect. The preparation method is simple, economic and practical, and facilitates industrialized batch production.

The invention relates to an oral capsule preparation of flunarizine hydrochloride and a preparation method thereof, belonging to the technical field of medicines. The capsule comprises the following components in parts by weight: 58-60 parts of flunarizine hydrochloride, 114-115 parts of starch, 212.6-213 parts of 63 percent ethanol, 35.3-35.5 parts of sodium carboxymethyl starch and 11.6-12 parts of magnesium stearate. The flunarizine hydrochloride disclosed by the invention has high quality stability, the quality of the flunarizine hydrochloride capsules is stable and controllable, and safety and effectiveness of clinical application are ensured.

Flunarizine hydrochloride matrix sustained-release tablets are prepared from, by weight, 25-55 parts of flunarizine hydrochloride, 35-55 parts of a matrix material, 5-10 parts of diluent, 3-5 parts of a binding agent and 2-5 parts of a lubricating agent. A preparing method of the flunarizine hydrochloride matrix sustained-release tablets comprises the following steps that flunarizine hydrochloride, the matrix material, the diluent the lubricating agent and the binding agent are mixed evenly and them directly pressed into the tablets in a powder mode or flunarizine hydrochloride, the matrix material, the diluent and the binding agent are mixed to be prepared into granules, the granules are then mixed with the lubricating agent evenly, and the tablets are obtained through tabletting. The flunarizine hydrochloride matrix sustained-release tablets overcome the defect that in the prior art, multiple times of administration needs to be conducted due to the short relative half-life period of flunarizine hydrochloride, and it can be avoided that to maintain the blood concentration with the effective amount to reach a treatment effect, initial over-doses in the initial administration period occur, and consequently many side effects are caused; the problem that due to insufficient doses, the pain of a patient cannot be relieved, and the treatment effect cannot be achieved is also solved.

The invention relates to a Flunarizine hydrochloride capsule and its preparing process, wherein the capsule contains ultramicro-powders of flunarizine hydrochloride with internal diameter less than 10 mum, and the preparing process comprises disintegrating Flunarizine hydrochloride raw material, mixing the obtained ultramicro-powder with starch and lactose, then mixing with talcum powder and magnesium stearate, finally loading into capsule and packaging.

The invention relates to the field of medical technology, and discloses a flunarizine hydrochloride composition capsule and a preparation method thereof. The flunarizine hydrochloride composition capsule comprises flunarizine hydrochloride, polyethyleneglycol, talcum powder, magnesium stearate, lactose and starch. As auxiliary material composition is changed, that is, flunarizine hydrochloride is added into polyethyleneglycol which is in a molten state, and then uniformly mixed with other auxiliary materials in an equivalently progressive increasing manner, the dissolution rate and the flowability of the end product are improved remarkably.

The invention discloses a method for detecting related substances of a flunarizine hydrochloride preparation, which comprises the following steps: respectively taking a test solution, a contrast solution and an impurity mixed solution for high performance liquid chromatography detection, and respectively detecting the content of each impurity in the test solution at 210nm and 253nm, wherein peaksof the impurity A and 4, 4-difluorobenzhydrol are detected at 210 nm, and the impurity content is calculated according to an external standard method; and detecting other impurity peaks at 253nm, andcalculating the impurity content according to a self-contrast method. The method is easy to operate, short in analysis time, high in specificity and high in sensitivity, seven impurities can be effectively separated, the separation degree of two process impurities and five degradation impurities, the most difficult-to-separate impurity B and a main peak reaches 1.2 or above, and the separation degree of other impurities and adjacent peaks can all reach 1.5 or above.

The invention relates to a pharmaceutical composition of ticagrelor and a type II therapeutic agent and a preparation method of the pharmaceutical composition. The pharmaceutical composition is characterized in that the type II therapeutic agent is selected from one or more of troxerutin, cinnarizine, flunarizine hydrochloride, ligustrazine, ligustrazine phosphate, sodium ferulate or piperazine ferulate. The invention also relates to application of the pharmaceutical composition in drugs, in particular the application in inhibiting or reversing of atherosclerosis lipid plaques of artery blood vessel.

The invention discloses a detection method for the dissolution determination of flunarizine hydrochloride capsules. The method is characterized in that a dissolution method is a paddle method in whichthe speed is 100 revolutions per minute; a medium of lauryl sodium sulfate is added to serve as a dissolution medium; a dissolved matter is detected by high performance liquid chromatography; octadecyl silane bonded silica gel is taken as a filling agent; the detection wavelength of an ultraviolet detector is 251 to 255nm; the column temperature is 25 to 45 DEG C; the flow rate is 0.9 to 1.1ml/min; and a flowing phase is prepared from methane and a phosphate Buffer solution. Through adoption of the method, the problem concerned with flunarizine hydrochloride capsule filter membrane adsorptionis solved; an obtained chromatographic peak has a good peak pattern; high column efficiency and a more accurate result can be achieved; the service life of a chromatographic column is prolonged; andthe test cost is lowered.

The invention relates to a preparation method for a flunarizine hydrochloride crystal. The invention relates to a preparation method for a flunarizine hydrochloride crystal with a particle size of 20-30 microns. The preparation method comprises the following steps: firstly, adding flunarizine hydrochloride into an aqueous solution of a low-boiling-point organic solvent; carrying out reduced-pressure evaporation at a temperature of 50-80 DEG C and a vacuum degree of 0.03-0.08 MPa, evaporating out a part of the solvent at an evaporation rate of 10-25%/h of the total amount of the solvent, performing crystal growing for 30-60 min after the crystal is separated out, then continuously carrying out reduced-pressure evaporation, and stopping evaporation and performing crystal growing when the volume of a distillate is 30-65% of the volume of the solvent; carrying out cooling to 5-10 DEG C at a cooling speed of 5-10 DEG C/h, and maintaining the temperature for crystal growing for 30-60 min; and carrying out filtering, and washing a filter cake with a solvent. The invention provides the preparation method for the flucinarizine hydrochloride crystal with controllable granularity.

The present invention relates to a kind of flunarizine hydrochloride dripping pills. It is made up by using flunarizine hydrochloride as active component, using polyethylene glycol as matrix and adopting a diameter-limited cylindrical concave orifice dripping-head dripping preparation process to produce the invented flunarizine hydrochloride dripping pills. The weight of every pill is 5mg-100mg.

The present invention provides a flunarizine hydrochloride bulk injection and its production process. Its preparation range, every ampule contains 2mg-50mg of flunarizine hydrochloride and 0.1 ml-10 ml of 1.2-propylene glycol, the solvent respectively can be glucose, sodium chloride and glucose sodium chloride, and their contents respectively are 1g-50g of glucose and 0.3g-10g of sodium chloride. Its production process includes the following steps: placing 20ml of 1.2-propylene glycol in a container, then adding flunarizine hydrochloride, in said container, heating, stirring and dissolving; using injection water to dissolve glucose, stirring, adding it into container, diluting and dissolving, adding injection water to full dose, adding active carbon, heating to 80-90 deg.C, heat-insulating for 15 min., filtering and removing carbon, secondary filtering, adding flurnarizine hydrochloride and 1.2-propylene glycol mixed liquor, stirring them uniformly, regulating pH to 3.5-5.0 so as to obtain the invented product.

The invention provides a histamine receptor inhibitor and derivatives thereof in the preparation of anti-Zika virus drugs. The histamine receptor inhibitor is preferably one or more of mebhydrolin napadisylate, ketotifen fumarate, flunarizine hydrochloride, cyproheptadinehydrochloride, JNJ-7777120, desloratadine, brompheniramine maleate, brompheniramine maleate, chlorpheniramine maleate and cetirizine hydrochloride. The invention brings forward for the first time that the histamine receptor inhibitor and its derivatives have clear anti-Zika virus effect and can significantly inhibit the expression level of Zika virus protein and Zika virus RNA. The invention also screens out histamine receptor inhibitors with better inhibitory effect on Zika virus, including mebhydrolin napadisylate, cyproheptadinehydrochloride, JNJ-7777120, desloratadine, etc., whose inhibition effect on Zika virus at a concentration of 10 uM is equivalent to inhibition effect of ribavirin at a concentration of 40 uM.The histamine receptor inhibitor and the derivatives can be used as good candidate drugs for anti-Zika virus drugs.

The invention relates to compound flunarizine hydrochloride and a preparation process thereof. The compound flunarizine hydrochloride is prepared from the following raw materials in part by weight: 0.7 part of flunarizine hydrochloride, 25 parts of root of red-rooted salvia, 20 parts of common burreed rhizome, 18 parts of zedoary, 15 parts of tall gastrodia tuber and 10 parts of glossy privet fruit, starch live edible cellulose serving as a pharmaceutic adjuvant are added according to the conventional pharmaceutic method to prepare formulations such as capsules, tablets, granules and the like. The compound flunarizine hydrochloride medicinal composition addresses both root causes and symptoms on epilepsy, is non-toxic and harmless to human bodies, does not have side effect, is low in costand easy and convenient to prepare, and has a bright application prospect.

The invention discloses a flunarizine hydrochloride capsule preparation and a preparation method thereof. The flunarizine hydrochloride capsule preparation is prepared from the following raw materials in parts by weight: 2-10 parts of flunarizine hydrochloride, 100-150 parts of lactose, 10-40 parts of starch, 0.1-1 part of a flow aid and 2-20 parts of a lubricant. The flunarizine hydrochloride capsule prepared by the invention is placed for 3 months under a high-temperature experimental condition, the dissolution curve of the flunarizine hydrochloride capsule in a medium with a pH value of 3.0 has no obvious change, and an f2 value is greater than 50; and the dissolution curve of an original developed preparation is obviously reduced, and the f2 value is 12.7. The in-vitro dissolution curve stability of the flunarizine hydrochloride capsule prepared by the invention is superior to the in-vitro dissolution curve stability of the original preparation.

The present invention discloses a flunaizine hydrochloride freeze-dried preparation for injection. Its composition includes (by wt%) 1-50% of flunarizine hydrochloride and 50-99% of auxiliary material, said auxiliary material is mannitol or mannitol composite. Its preparation includes the following steps: a), uniformly mixing flunarizine hydrochloride and medicinal auxiliary material, using acid or alkali to regulate pH value to 2.0-3.5; b), adding 0.01%-0.1% of active carbon, stirring at room temperature, filtering, removing heat source, filtering and sterilizing; c), quickly cooling to-30-50 deg.C, retaining for 2-6 hr.; and d), vacuum freezing, drying and sealing.

The invention discloses a western medicine composition for treating lame impediment. The western medicine composition for treating lame impediment is prepared from the following raw materials in parts by weight: 1-5 parts of catechin, 5-13 parts of North America eriodictin, 11-19 parts of flunarizine hydrochloride and 3-7 parts of benzophenone. A preparation method comprises the following steps: mixing catechin with North America eriodictin and grinding, adding deionized water, and carrying out stirring treatment for 38-40 minutes at the temperature of 73 DEG C, so that a mixture A is obtained; and mixing the prepared benzophenone solution with the mixture A, carrying out stirring treatment for 12 minutes at the temperature of 68 DEG C, adding catechin, then carrying out ultrasonic treatment for 25 minutes at the temperature of 50 DEG C, then stirring until dry at the temperature of 60 DEG C, and granulating, so that the western medicine composition for treating lame impediment is obtained. The western medicine composition can treat both symptoms and root causes of lame impediment and has the characteristics of definite effect and quick healing, near-term and long-term curative effects are respectively better than those of a non-steroidal anti-inflammatory western medicine, and the western medicine composition disclosed by the invention is low in dosage, has no toxic or side effect and no allergy reaction and is high in curative ratio, low in recurrence rate, low in price and easily acceptable to patients.